HOME >> MEDICINE >> NEWS
Lexapro receives FDA approval for the treatment of generalized anxiety disorder

NEW YORK, December 18 - Forest Laboratories, Inc. (NYSE:FRX) announced today that the U.S. Food and Drug Administration (FDA) has approved Lexapro (escitalopram oxalate), a selective serotonin reuptake inhibitor (SSRI), for the treatment of generalized anxiety disorder (GAD), a condition that affects approximately four million Americans annually. The new indication is based on three studies, all of which were positive and support the efficacy and safety of Lexapro in the treatment of GAD. GAD is characterized by excessive anxiety and worry that significantly impacts an individual's daily functioning. Lexapro is also indicated for the initial treatment and maintenance of major depressive disorder.

"One of the biggest challenges in treating GAD patients is finding a treatment that is not only effective, but also one that patients will be able to tolerate for the long term," said Philip Ninan, M.D., professor of Psychiatry and Behavioral Sciences and director of the Mood and Anxiety Disorders Program at Emory University School of Medicine. "Lexapro is a first-line treatment option, which has proven to be effective with a favorable side effect profile."

Study Details

All three studies that support the indication approval were randomized, double-blind, eight weeks in duration and placebo-controlled. The studies involved approximately 850 patients, 18 to 80 years of age, diagnosed with GAD. Patients in the Lexapro arm were administered a fixed dose of 10 mg per day for the first four weeks and then flexibly dosed to a maximum of 20 mg per day. The Hamilton Anxiety Scale (HAMA) total score was the primary efficacy variable, and secondary efficacy measures included changes in HAMA psychic anxiety subscale and Clinical Global Impressions (CGI) scores. In each of the three studies, Lexapro 10 to 20 mg per day significantly improved GAD symptoms in patients compared to placebo as measured by change from baseline in HAMA score. By-visit anal
'"/>

Contact: Charles E. Triano
212-224-6714
Forest Laboratories
18-Dec-2003


Page: 1 2

Related medicine news :

1. Starting dose of Lexapro as effective as optimally dosed Zoloft in the treatment of depression
2. UIC professor receives international humanitarian award
3. Mailman School of Public Health receives Manhattan Tobacco Cessation Center grant
4. Epidemiologist Trichopoulos receives $5.8 million Department of Defense Innovator Award
5. GlaxoSmithKline receives unanimous favorable recommendation by FDA Advisory Committee for Boostrix
6. NYU Child Study Center receives grant from the American Red Cross September 11 recovery program
7. Northwestern Memorial Hospital receives $10 million commitment to support preeminent heart program
8. American Academy of Neurology program receives Grassroots Award
9. Orqis receives FDA approval to expand clinical trial of Cancion CRS therapy to 40 centers
10. Mayo Clinic Cancer Center receives SPORE grant for brain cancer research from NCI
11. Pfizers antifungal medicine VFEND receives FDA approval

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/26/2016)... ... May 26, 2016 , ... An April Gallup survey found rising ... 550 employees of Sun Health Senior Living (SHSL) may not share those ... doctor and prescription copays for the year, while holding the line on increasing their ...
(Date:5/26/2016)... ... May 26, 2016 , ... The Lung Institute ... a six-week smoking cessation class starting June 6 at their clinic in downtown Tampa. ... . , Additionally, the Lung Institute has created a free downloadable 4 Week ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... Top Doc! Along with his wonderful accolades and stellar patient reviews, Dr. Batelli ... Dr. Batelli! , Dr. Eugene Batelli is a highly trained Podiatric Surgeon who ...
(Date:5/26/2016)... ... May 26, 2016 , ... A health conscious snack that doesn't ... Bar, has ignited an undeniable buzz in the protein product community by offering ... any doughnut.  These doughnuts are packed with 11 grams of protein and made from ...
(Date:5/26/2016)... York, NY (PRWEB) , ... May 26, 2016 , ... ... have lips been so central to popular cosmetic improvement efforts. Record numbers of clients ... kissers appear more prominent or pouty, says Kally Papantoniou, MD, of Advanced Dermatology ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... , May 24, 2016 ... beide primären Endpunkte und demonstriert ... in ‚ausgezeichneter plus guter , ...    ,      (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ... heute neue positive Daten von der MORA-Studie der ...
(Date:5/24/2016)... 2016 Celsion Corporation (NASDAQ: ... provided an update on its ongoing OVATION study, ... GEN-1, the Company,s DNA-based immunotherapy, with the standard ... with advanced ovarian cancer who will undergo neoadjuvant ... an IL-12 DNA plasmid vector formulated as a ...
(Date:5/24/2016)... May 24, 2016 Open Access ... Clinical Neurophysiology  Elsevier , a world-leading ... services, today announced the launch of Clinical ... journal that focuses on clinical practice issues in clinical ... clinical series, normal values and didactic reviews. It is ...
Breaking Medicine Technology:
Cached News: